EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study

Hedda S Riise iD, Melanie R Simpson, Ketil A Espnes, Erling A Tronvik, Andreas K Husøy, Lise R Øie, Anker Stubberud iD, Emil Kofoed, Aurora H Alstad, Hedda H Hagen, Maren G Lien, Marie L Stavseng und 2 weitere

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70061 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Hedda S Riise und 13 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Research and Innovation funding programme, Stolav's University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the adherence, effectiveness, safety, tolerability, and acceptability of frequently used oral migraine preventive drugs in a real‐world setting.

Background

Oral migraine preventives are previously mainly explored in randomized controlled trials, whereas real‐world data on treatment outcomes remain limited.

Methods

MigriNor was a prospective observational cohort study conducted from May 2021 to June 2024 at St. Olav's University Hospital, Trondheim, Norway. The study included participants with migraine who started oral preventive treatment, including candesartan, amitriptyline, metoprolol, or topiramate. Migraine diagnosis, according to the ICHD‐3, was verified by a neurologist at inclusion. Participants recorded daily entries in an electronic headache diary during a 4‐week baseline period before beginning treatment, followed by a 12‐week follow‐up period with telephone consultations every 4 weeks. If a change of preventive drug was necessary, participants were allowed to re‐enter the study using the same baseline period. Change from baseline in moderate‐to‐severe headache days was the primary effectiveness endpoint. Drug acceptability outcomes were collected at 12 weeks or at the time of discontinuation.

Results

A total of 254 participants were included, 51.2% of them had chronic migraine and 48.8% had episodic migraine. Of all participants, 6.7% had previous treatment failure of at least three preventive drugs and 18.1% had baseline medication overuse. Candesartan and amitriptyline demonstrated similar reductions in moderate–severe headache days from baseline to weeks 9 to 12 (−2.4 days, 95% confidence interval: [−3.0 to −1.9], p < 0.001 for candesartan, and −2.4 days, 95% confidence interval: [−3.1 to −1.6], p < 0.001 for amitriptyline). The study was unable to detect a significant reduction of moderate–severe headache days from baseline to weeks 9 to 12 for metoprolol and topiramate, but both demonstrated effectiveness for several secondary outcomes. High proportions of participants (22.3% to 46.8%, depending on the drug used) discontinued preventive treatment before 12 weeks. Candesartan had the lowest mean number of adverse drug reactions (1.3), the lowest proportion of participants experiencing at least one adverse drug reaction (77.1%), and high acceptability. Topiramate had the highest mean number of adverse drug reactions (4.2), a large proportion of participants experiencing at least one adverse drug reaction (95.7%), and low acceptability.

Conclusion

Because this was an observational study characterized by imbalanced group sizes and absence of randomization, the comparability across drugs was limited. Candesartan and amitriptyline both significantly reduced the number of moderate–severe headache days with candesartan having fewer adverse events and higher acceptability. A significant reduction in moderate–severe headache days was not detected for topiramate and metoprolol, but both demonstrated effectiveness for several other measured outcomes. Topiramate had severe acceptability issues, whereas metoprolol had intermediate acceptability. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAdultFemaleHumansMaleMiddle AgedAdministration, OralAmitriptylineBenzimidazolesBiphenyl CompoundsMetoprololProspective StudiesTetrazolesTopiramateTreatment Outcome

Stichwörter der Autor:innen

amitriptylinecandesartanmetoprololmigraineprophylaxistopiramate

Substanzen

AmitriptylineBenzimidazolesBiphenyl CompoundscandesartanMetoprololTetrazolesTopiramate

Autor:innen und Institutionen

  • Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Neurology and Neurophysiology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Faculty of Information Technology and Electrical Engineering, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

ORCID-Profile: Hedda S Riise, Anker Stubberud

Förderung

  • The Research and Innovation funding programme, Stolav's University Hospital

Zitieren

APA

Riise, H. S., Simpson, M. R., Espnes, K. A., Tronvik, E. A., Husøy, A. K., Øie, L. R., Stubberud, A., Kofoed, E., Alstad, A. H., Hagen, H. H., Lien, M. G., Stavseng, M. L., Sæther, E. R., & Wergeland, T. (2026). Effectiveness and acceptability of oral migraine preventives: A prospective, observational study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70061

Vancouver

Riise HS, Simpson MR, Espnes KA, Tronvik EA, Husøy AK, Øie LR, et al. Effectiveness and acceptability of oral migraine preventives: A prospective, observational study. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70061

BibTeX
@article{Riise2026,
  author = {Riise, Hedda S and Simpson, Melanie R and Espnes, Ketil A and Tronvik, Erling A and Husøy, Andreas K and Øie, Lise R and Stubberud, Anker and Kofoed, Emil and Alstad, Aurora H and Hagen, Hedda H and Lien, Maren G and Stavseng, Marie L and Sæther, Ella R and Wergeland, Tore},
  title = {Effectiveness and acceptability of oral migraine preventives: A prospective, observational study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70061}
}
Kostenlos starten →